VRPX (Virpax Pharmaceuticals) EV-to-EBIT: 0.12 (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Virpax Pharmaceuticals EV-to-EBIT?

Virpax Pharmaceuticals VRPX EV-to-EBIT is 0.12 as of Jul. 19, 2026.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Virpax Pharmaceuticals's Enterprise Value is $-1.50 Mil. Virpax Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-12.05 Mil. Therefore, Virpax Pharmaceuticals's EV-to-EBIT for today is 0.12.

The historical rank and industry rank for Virpax Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

VRPX's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 13.255
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Virpax Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2024 was $4.15 Mil. Virpax Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-12.05 Mil. Virpax Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -290.42%.

Virpax Pharmaceuticals  (OTCPK:VRPX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Virpax Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 ) =EBIT / Enterprise Value (Q: Dec. 2024 )
=-12.045/4.14751
=-290.42 %

Virpax Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2024 was $4.15 Mil.
Virpax Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virpax Pharmaceuticals EV-to-EBIT Related Terms

Virpax Pharmaceuticals EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Virpax Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virpax Pharmaceuticals EV-to-EBIT Chart

Virpax Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial 0.00 -0.29 0.53 0.32 -0.35

Virpax Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 -0.17 0.02 -0.23 -0.35

VRPX vs SYGGF, SCPX, LADX: EV-to-EBIT Comparison

For the Biotechnology subindustry, Virpax Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virpax Pharmaceuticals EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virpax Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Virpax Pharmaceuticals's EV-to-EBIT falls into.


Virpax Pharmaceuticals EV-to-EBIT Calculation

Virpax Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-1.499/-12.045
=0.12

Virpax Pharmaceuticals's current Enterprise Value is $-1.50 Mil.
Virpax Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-EBIT →
What does a EV-to-EBIT of 0.12 mean?
Virpax Pharmaceuticals (VRPX) has a EV-to-EBIT of 0.12 as of Jul. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Virpax Pharmaceuticals and its competitors.
Is Virpax Pharmaceuticals' EV-to-EBIT too high?
Virpax Pharmaceuticals' current EV-to-EBIT is 0.12. The Biotechnology industry median EV-to-EBIT is 13.26. Virpax Pharmaceuticals' value of 0.12 is 99.1% below this industry median.
How does Virpax Pharmaceuticals' EV-to-EBIT compare to SYGGF and SCPX?
Virpax Pharmaceuticals' EV-to-EBIT of 0.12 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBIT is 13.26. Virpax Pharmaceuticals' value of 0.12 is 99.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.26, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virpax Pharmaceuticals's current EV-to-EBIT of 0.12 is 99.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Virpax Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virpax Pharmaceuticals's current EV-to-EBIT is 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virpax Pharmaceuticals stock overvalued right now?
Virpax Pharmaceuticals (VRPX) has a current EV-to-EBIT of 0.12. The current EV-to-EBIT is 0.12 and 99.1% below the Biotechnology industry median of 13.26. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Virpax Pharmaceuticals (VRPX), the current EV-to-EBIT is 0.12 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Virpax Pharmaceuticals Business Description

Address 1055 Westlakes Drive, Suite 300, Berwyn, PA, USA, 19312
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.